Covaxine: Volunteers selected, human trials of India’s first COVID-19 vaccine begin at AIIMS Patna
New Delhi | Jagran News Desk: Hyderabad-based Bharat Biotech-led Coronavirus vaccine effort has reached the clinical trial phase, with 18 volunteers selected for its human trial at AIIMS Patna. Worldwide, according to a New York Times report, a total of 155 vaccines are in different stages of development, of which 22 have reached human trial stage, with Bharat Biotech’s ‘Covaxine’ being one among them.
All about ‘Covaxine’ so-far
Bharat Biotech’s vaccine candidate reportedly developed an ‘effective’ immune response during the pre-clinical phase of its trials between late-June and early-July. Covaxine is an inactivated vaccine that utilizes the dead novel Coronavirus vaccine to evoke an immune response against the contagion virus. The vaccine is being developed by Bharat Biotech, in collaboration with National Institute of Virology, Pune.
Where will human trial take place?
The Indian Council of Medical Research has selected 12 medical institutes from all over the country, that are supposed to begin the clinical trials of Covaxine in the volunteers aged eighteen to fifty-five. AIIMS New Delhi, and AIIMS Patna will start the initial part of Human trials of the vaccine.
How will human trial take place?
The Indian Council for Medical Research has specific Standard Operating Procedures in place, that make it mandatory for the selected volunteers to undergo a standardised medical check ups, reports of which are utilised to determinen whether the volunteer can be given the dosage of vaccine under trial or not.
All eighteen volunteers at AIIMS Patna will undergo these checkups before being trialed with the vaccine dosage.
How many vaccine dosages will be given to the volunteers?
A total of three doses of the vaccine under trial will be given to the volunteers. After each dosage, the volunteer will remain under observation for two to three hours, according to ICMR guidelines.
Russian vaccine claims successful human trial
Researchers at Russia’s Sechenov University claimed the success of its vaccine candidate in its clinical (human-trial) phase as well. First group of volunteers were reportedly given the vaccine on June 16th, and successive dosages after that reportedly showed effective immune response in the human bodies. The vaccine currently awaits the prototype approval from Russian authorities, after which vaccine’s passage towards general public might become clearer.
Chinese vaccine maker Cansino Biologics too, is in the mid of its vaccine candidate’s human trials, the feasibility of which so-far awaits the completion of the trial stage
Posted By: Abhinav Gupta